kabutan

AnGes, Inc.(4563) Summary

4563
TSE Growth
AnGes, Inc.
60
JPY
+1
(+1.69%)
Jan 29, 3:07 pm JST
0.39
USD
Jan 29, 1:07 am EST
Result
PTS
outside of trading hours
59.5
Jan 29, 3:09 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.69
Yield
ー%
Margin Trading Ratio
8.26
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
60 JPY 0.39 USD
Previous Close Jan 28
59 JPY 0.38 USD
High Jan 29, 9:00 am
60 JPY 0.39 USD
Low Jan 29, 9:01 am
59 JPY 0.38 USD
Volume
274,400
Trading Value
0.02B JPY 0.11M USD
VWAP
59.41 JPY 0.39 USD
Minimum Trading Value
6,000 JPY 39 USD
Market Cap
0.02T JPY 0.15B USD
Number of Trades
119
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
692
1-Year High Aug 12, 2025
5,987
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,320,200 32,839,300 24.87
Jan 16, 2026 1,357,300 32,467,700 23.92
Jan 9, 2026 1,372,500 32,578,400 23.74
Dec 26, 2025 1,372,500 32,060,600 23.36
Dec 19, 2025 1,264,600 32,775,600 25.92
Company Profile
AnGes, Inc. is a biotech venture founded by an Osaka University professor, developing gene therapies and other pharmaceuticals. The company also sells treatments for intractable diseases.
Sector
Pharmaceuticals
AnGes, Inc. is a biotech venture originating from Osaka University Medical School, focusing on the development and sale of pharmaceuticals, particularly gene therapies. The company also provides contract testing services, primarily for rare genetic disease screening. Its subsidiary, EmendoBio Inc., possesses advanced genome editing technologies and is engaged in research and development of new treatments using genome editing products. In 2019, AnGes obtained conditional and time-limited manufacturing and marketing approval for "Collategene," the world's first plasmid DNA-based gene therapy product. The company has entered into an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for the Japanese market, and has begun sales, recording product sales revenue.